The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

Abstract

Background Omalizumab is a third‐line treatment for chronic spontaneous urticaria (CSU). However, the real‐life data on the impact of omalizumab on CSU‐related quality of life (QoL) remain scarce. Objectives To investigate the impact of omalizumab on QoL and its predictors in CSU. A retrospective cohort study was done. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT); the impairment in QoL was assessed using dermatology life quality index (DLQI) and chronic urticaria quality of life questionnaire (CU‐Q2oL). Results Forty‐two patients were included. All scores improved from baseline to first month and remained stable at the third month of treatment (p < .001). The gender, age, and angioedema had no significant effect on QoL, but the complete responders (UAS7:0–1) had better improvement rates in all scores compared to others. The baseline UAS7, DLQI, and CU‐Q2oL scores were lower at the baseline in complete responders (p = .0001). Conclusions A rapid and continual improvement in QoL was obtained with omalizumab treatment. A better UAS7, UCT, DLQI, and CU‐Q2oL score at the baseline might be a predictor of a better response to omalizumab and more improvement in QoL.

The effect of at least 1‐year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria

“…But, we did not include these patients group in this study because we evaluated only standart OMA regime. 4,5,11,12 In line with the literature, this study found that the prevalence of CSU was higher in females. When males and females were compared in our study, the risk of relapse was not higher in female patients, as in the study by Marzano et al 13,14 In our study, 78% of the patients (39 patients) had complete remission at the end of 12 months.…”

“…Multiple factors may be involved in the clinical and prognostic polymorphism of CSU. [3][4][5] The guidelines for the treatment of CSU recommend the use of second-generation nonsedating H1-antihistamines for initial therapy and suggest up-dosing of these antihistamines up to 4-fold in patients with CSU who are unresponsive to standard doses. When they fail to achieve success, the guidelines recommend the use of omalizumab (OMA) as third-line therapy.…”

“…Treatment response and disease course vary in each patient. Multiple factors may be involved in the clinical and prognostic polymorphism of CSU 3‐5 . The guidelines for the treatment of CSU recommend the use of second‐generation nonsedating H1‐antihistamines for initial therapy and suggest up‐dosing of these antihistamines up to 4‐fold in patients with CSU who are unresponsive to standard doses.…”

Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress

“…Accordingly, the meta-analysis of real-life studies has shown a mean AE rate of 4% [14]. Moreover, the positive impact of omalizumab on various aspects of patient QoL has also been also demonstrated in clinical trials and real-life studies [41][42][43]. Yet, there are still some obscurities and challenges regarding the use of omalizumab for CSU.…”

How to control recurrent angioedema using monoclonal antibody therapies?

“…Less than 50% of patients with RA due to CSU achieve complete disease control and freedom of attacks with this [23]. Those who do not are recommended to treat with omalizumab, which benefits up 80% of them (see Table 2) [24].…”